BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hafezi M, Lin M, Chia A, Chua A, Ho ZZ, Fam R, Tan D, Aw J, Pavesi A, Krishnamoorthy TL, Chow WC, Chen W, Zhang Q, Wai LE, Koh S, Tan AT, Bertoletti A. Immunosuppressive Drug-Resistant Armored T-Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients. Hepatology 2021;74:200-13. [PMID: 33249625 DOI: 10.1002/hep.31662] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu J, Mau Lo C, Man K. Role of Intrahepatic Regional Immunity in Post-Transplant Cancer Recurrence. Engineering 2021. [DOI: 10.1016/j.eng.2021.11.012] [Reference Citation Analysis]
2 Hafezi M, Tan A, Bertoletti A. Personalized Armored TCR-Redirected T Cell Therapy for Liver/Organ Transplant with Recurrent Cancer. Cells 2021;10:1861. [PMID: 34440630 DOI: 10.3390/cells10081861] [Reference Citation Analysis]
3 Luo Y, Teng F, Fu H, Ding GS. Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons. World J Gastrointest Oncol 2022; 14(1): 163-180 [DOI: 10.4251/wjgo.v14.i1.163] [Reference Citation Analysis]
4 Lam M, Reales-Calderon JA, Ow JR, Adriani G, Pavesi A. In vitro 3D liver tumor microenvironment models for immune cell therapy optimization. APL Bioeng 2021;5:041502. [PMID: 34632251 DOI: 10.1063/5.0057773] [Reference Citation Analysis]
5 Lu F, Ma XJ, Jin WL, Luo Y, Li X. Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges. Front Immunol 2021;12:690565. [PMID: 34054880 DOI: 10.3389/fimmu.2021.690565] [Reference Citation Analysis]
6 Tan AT, Meng F, Jin J, Zhang JY, Wang SY, Shi L, Shi M, Li Y, Xie Y, Liu LM, Zhou CB, Chua A, Ho ZZ, Luan J, Zhao J, Li J, Wai LE, Koh S, Wang T, Bertoletti A, Wang FS. Immunological alterations after immunotherapy with short lived HBV-TCR T cells associates with long-term treatment response in HBV-HCC. Hepatol Commun 2021. [PMID: 34935312 DOI: 10.1002/hep4.1857] [Reference Citation Analysis]
7 Tan AT, Bertoletti A. HBV-HCC treatment with mRNA electroporated HBV-TCR T cells. Immunotherapy Advances 2022;2:ltab026. [DOI: 10.1093/immadv/ltab026] [Reference Citation Analysis]